Rgenix, a small molecule and antibody cancer treatment drug research and development company, received $40 million in Series C financing
It is learned that Rgenix, a biopharmaceutical company focused on the development of new drugs for small molecule and antibody cancer treatment, has received $40 million in Series C financing. This round of financing was led by global medical company Lepu Medical, which included new investors Oceanpine Capital and WuXi AppTec's Corporate Venture Fund, as well as old investors Novo Holdings A/S, Sofinnova Partners, Alexandria Venture Investments, LLC and New York City Innovation New York Fund and its related cooperative funds. Jefferies LLC served as financial advisor to Rgenix in this round of financing. Previously, Rgenix was awarded a $33 million Series B round of financing by Novo Holdings and Sofinnova Partners in June 2016. Since its inception in 2010, Rgenix has received a total of $83.5 million in financing.
Rgenix will use this round of financing to advance its clinical and preclinical oncology drug development projects and the company's daily operations, primarily to advance Phase 1b / 2 clinical trials of RGX-104 for multiple cancer indications, and will also use Early clinical development of RGX-202.
Pu Pujie, CEO and Chairman of Lepu Medical, said: “Lepu Medical is proud to invest in Rgenix. We are very optimistic about Rgenix's unique mRNA discovery platform, and Rgenix can use this platform to develop the first innovative drugs for various cancer cell targets. We also believe RGX-104 has great potential for checkpoint inhibitors in many types of cancer. Currently, Lepu Medical has conducted clinical trials of PD-1, PD-L1 checkpoint inhibitors and oncolytic viruses, so we are also looking forward to Rgenix Explore possible opportunities for collaboration and achieve our common goal of further development in the cancer market."
Rgenix's drug discovery platform recognizes new targets for RNA-regulated cancer cells of various types of solid tumors. The mRNA platform was originally developed by Rgenix's scientific co-founder at Rockefeller University, and Rgenix has now obtained exclusive licenses for the platform. Currently, Rgenix's R&D pipelines mainly include:
RGX-104 is a new oral small molecule initiative that prevents tumors from escaping the immune system and improving drug resistance. RGX-104 targets the liver X receptor (LXR), which activates the APOE gene to regulate innate immunity by regulating the two types of innate immune system cells MDSCs (consuming myeloid-derived cells) and DCs (dendritic cells) Active treatment of cancer. MDSCs can block T cell activation, while DC cells can activate T cells. RGX-104 can consume MDSCs and stimulate DCs to induce anti-tumor activity in the human immune system. RGX-104 has potential efficacy as a monotherapy or in combination with immunotherapy such as PD-1 inhibitors.
RGX-104 has been approved by the US FDA for the approval of orphan drugs for the treatment of melanoma, glioblastoma multiforme (GBM) and ovarian cancer. At the same time, Rgenix also obtained GlaxoSmithKline (GSK) RGX-104 and other LXR intellectual property licenses. Currently, RGX-104 is conducting Phase 1b/2 clinical trials in combination with Opdivo for the treatment of a variety of cancers, including ovarian cancer and non-small cell lung cancer. The results of the trials show that monotherapy also has immunostimulatory and antitumor activities.
RGX-202 is a novel small molecule compound that inhibits the metabolism of cancer cells. It inhibits creatine synthesis by targeting the creatine transporter SLC6a8, thereby inhibiting the conversion of creatine to ATP to provide energy for cancer cell activity. Preclinical studies have shown that RGX-202 can be used alone or in combination with other standard chemotherapy to treat gastrointestinal to cancer. Rgenix expects to conduct RGX-202 studies including colon cancer, rectal cancer and gastric cancer in the middle of 2018.
RGX-019 is a monoclonal antibody targeting MerTK for the treatment of solid tumors. Working with Rockefeller University, Rgenix identified MerTK, a receptor tyrosine kinase of the TAM family, as a novel target for triple negative breast cancer (TNBC) using its unique microRNA platform. Rgenix will conduct the IND study of RGX-019 in 2019.
Rgenix's mRNA platform (from Rgenix's official website)
Founded in 2010 and headquartered in New York, Rgenix is ​​a privately held clinical stage biopharmaceutical company. Rgenix is ​​focused on developing new anticancer drugs related to the critical processes of cancer. Currently, the company is developing several first innovative drugs to meet the therapeutic needs of cancer patients. Rgenix's microRNA platform recognizes new cancer targets and is a major innovation in cancer biology.
Nootropics powder or Nootropics, are a diverse group of cognitively enhancing compounds that are classified as lassi, plant, Vitamin and fuel
I. Lassie drugs to promote wisdom
Rasciates are based on the compound piracetam and tend to work by enhancing the corpus callosum (the brain region that connects the two hemispheres), which can positively affect creativity and speech, acting as a glutamate or AMPA regulator (a subclass of neural receptors involved in learning and memory), brain circulation, brain metabolism, and more.
Lassi is the first class of psychotropic drugs that have been studied based on the naturally occurring amino acid Pyroglutamate (5-oxopyrrolidine-2-carboxylicacid). Most of them work by using glutamate receptors as agonists (compounds that mimic or enhance receptor activity) to enhance and enhance cognitive function. They are non-toxic, safe and do not have any addictive effects.
Piracetam, known chemically as 2-oxo-1-Pyrrolidineacetamide, is the most popular of the rascicidal drugs. Piracetam is known as nootropil in other countries. Piracetam is water soluble and is the best Nootropics studied. Piracetam is used in more than 100 countries and has been shown to improve articulation, memory, concentration, overall cognition and more.
Anisetan (anethacetam) is a fat-soluble form of piracetam, which is known in some countries as Ampamet. It's fat-soluble, and it's an ampakine drug (a class of compounds being developed by DARPA to create mind-enhancing super-soldiers).
NeuroPEPT, chemically known as n-phenylacetyl-L-Prolylglycineethylester, is a novel aminate glycine and a precursor of a naturally occurring peptide in the human brain. It is 1000 times more effective than piracetam and has high bioavailability. It is considered to be the third generation of lasciform nootropics.
2. Plant drugs promoting wisdom
These compounds are found in plants (or produced by plant compounds) to actively support cognitive or emotional health. Huperzine A (L-hupezine) is a common example of a plant nootropics. Huperzine A is an alkaloid extracted from the endemic Chinese plant Huperzine. Studies around the world have found that huperzine A can enhance memory, improve memory impairment, improve the efficiency of mental activities, senile memory decline and alzheimer's disease, adolescent learning disability and memory enhancement have significant improvement effect.
Three, vitamin drugs to promote wisdom
These compounds of vitamin stimulants have improved absorption, nootropic effects, and reduced side effects. They are made from vitamins or natural compounds found in the brain. They are very safe and non-toxic and have a long history of research and use around the world.
Enhanced versions of vitamins or related compounds are more effective than their counterparts. Such drugs include edibenquinone (associated with coenzyme Q), pyrimercaptan (associated with vitamin B-6), Picamillon (associated with GABA and vitamin B-3), Fenebute (associated with GABA), methylchlorophenol hydrochloride (associated with dimethylaminoethanol), and more.
Iv. Fuel drugs promoting wisdom
Fuel enhancers are compounds that act as precursors of major neurotransmitters and act as "fuel" for the brain. Such drugs include :ALC, phosphocholine, cyticoline, DMAE, chlorophenol hydrochloride ester, theanine, tyrosine, etc.
Citicoline is a source of choline that has been shown to improve memory and cognitive function. Citicoline is a water-soluble nootropic of the choline chemistry. CDP choline can be used to increase dopamine receptor density and is reasonably used to treat or contribute to ADHD. Acetylcholine is a neural receptor involved in memory processes and development in the brain. Citicoline helps to promote brain health by increasing acetylcholine synthesis and development in the brain and restoring the level of lecithin. It helps increase brain glucose metabolism and brain blood flow.
Phosphocholine is a phospholipid metabolite found concentrated in the membranes of neurons. It comes from lecithin, which is very well absorbed and crosses the blood-brain barrier. In the brain, phosphocholine supports brain function and learning processes by directly increasing acetylcholine synthesis and secretion. Phosphocholine acts as a precursor membrane phospholipid to support neuronal health and improve signal transmission
best nootropic powder,nootropic powder to buy,buy Nootropic Powder
Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptide-nootropics.com